DarioHealth Integrates Digital Platform with Provider-Backed Clinical Care for GLP-1 Program
DarioHealth is launching an integrated GLP-1 program that combines its digital chronic care platform with provider-backed clinical care. Commercial availability is expected in Fall 2026.
DarioHealth has announced the launch of an integrated GLP-1 program, merging its digital chronic care platform with clinical services provided by healthcare professionals. This new offering is the first commercial product resulting from DarioHealth's collaboration with Beluga Health.
The program integrates licensed provider evaluations, prescription services, and ongoing clinical oversight directly within DarioHealth's existing chronic care platform. The aim is to provide a seamless, end-to-end experience for individuals requiring GLP-1 therapy.
Commercial availability for the program is targeted for Fall 2026. DarioHealth anticipates that revenue contributions from this new service will begin in late 2026. This expansion broadens the company's chronic disease management solutions.
DarioHealth, which focuses on digital solutions for chronic conditions, is entering the GLP-1 market to address the growing demand for these treatments. The company's platform provides tools and support for both patients and their care teams, facilitating better management of chronic diseases.